Clinical Trial Update: Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating a GLP-1/GIP analogue for non-alcoholic fatty liver disease in patients with type 2 diabetes; phase 1/2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• GLP-1/GIP analogue (glucose-dependent peptide analogue combining GLP-1 and GIP activity)

Snippet

Sponsor: Dr Adnan Agha | Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 1, Phase 2 | Status: UNKNOWN